Angelita Winters
|
 |
No recurrence was detected in 68 of 70 (97.1%) superficial BCCs and in 10 successfully treated nodular BCCs after 12 to 34 months of follow-up (mean 23 months). Adverse side effects were limited to local skin reactions. Aldara is for use antibiotics in patients with normal immune systems. Of the 49 enrolled patients, 1 discontinued the study and 1 was lost to follow-up. Aldara is not a cure for these conditions. Imiquimod ( Aldara ) treatment of superficial and nodular basal cell carcinoma. In our patient population, treatment of superficial BCCs with topical Imiquimod ( Aldara ) for 12 weeks produced an excellent clinical response overall, with complete remission maintained after a mean of 23 months. Two immunomodulatory agents, Imiquimod ( Aldara ) (Aldara), shown to be safe and effective in the management of anogenital warts, and alitretinoin gel, shown to be safe and antibiotics effective in the treatment of Kaposi's sarcoma, may offer a new therapeutic approach to treatment of cutaneous viral diseases. After 12 weeks of treatment, a complete response occurred in 70 of 75 (93.3%) superficial BCCs and a party response in 4 of 75 (5.3%) superficial acyclovir BCCs. This represents a new approach in the therapeutic treatment paradigm for treatment of cutaneous viral diseases at their site of infection.. Recurrence was observed in 2 of 70 (2.9%) successfully treated superficial BCCs 6 and 8 months after treatment discontinuation. To evaluate the efficacy, tolerability, and response durability of Imiquimod ( Aldara ) 5% cream in selected drug acyclovir patients with superficial and/or nodular BCCs. Facial herpes (herpes simplex virus-1 [HSV-1]), genital herpes (HSV-2), herpes zoster (varicella zoster virus), oral hairy leukoplakia (Epstein-Barr virus), Kaposi's sarcoma (HHV-8), molluscum contagiosum, condyloma acuminata (human papillomavirus [HPV-6, HPV-11]), plantar warts (HPV-1), and facial warts and dryasdust warts (HPV-5) are some of the cutaneous viral diseases most commonly seen in HIV-infected patients. Aldara may also be used to treat other conditions as determined by your doctor. 12-week open-label trial.BACKGROUND. Seventy-five superficial and 19 nodular BCCs in 49 patients were treated with Imiquimod ( Aldara ) once daily three times a week for up to 12 weeks. AK is caused by too much exposure. Imiquimod ( Aldara ) is an immune snappy comeback modifier shown to be effective in basal cell carcinoma (BCC). Ten of 19 (52.6%) nodular BCCs cleared after 12 weeks, whereas 7 (36.8%) sho partial remission. Immunomodulatory therapy in the management of viral infections in patients with HIV infection.Human immunodeficiency virus (HIV) causes disease by infecting lymphocytes and progressively destroying critical regulatory and effector cells of the immune system, leaving patients vulnerable to a number of bacterial, fungal, and viral infections. There is a strong scientific rationale to suggest that Imiquimod ( Aldara ) and alitretinoin gel may be useful in the treatment of a variety of cutaneous viral diseases that have been shown to respond to immunomodulatory drugs. Aldara is an immune response modifier (IMR) used to treat external genital and perianal warts in patients 12 years of age and older. Aldara (imiquimod). Aldara is also used to treat adults with certain types of precancerous skin lesions found on the face or scalp known as actinic keratosis (AK).
|